Table 2 Intergroup analysis of metabolic and vascular variables in patients treated with dulaglutide and controls at a 3 and 9 month follow-up
Variable | Three months follow-up | Nine months follow-up |
|---|---|---|
SBP (mmHg) (mean ± SD) | ||
 Subjects treated with dulaglutide | 134.9 ± 10.9 | 129.7 ± 10.7 |
 Controls | 133.7 ± 16.6 | 132.7 ± 16.7 |
 P | 0.653 | 0.264 |
DBP (mmHg) (mean ± SD) | ||
 Subjects treated with dulaglutide | 73.2 ± 9.9 | 71.8 ± 9.2 |
 Controls | 75.9 ± 9.1 | 75.9 ± 9.7 |
 P | 0.138 | 0.026 |
Weight (Kg) (mean ± SD) | ||
 Subjects treated with dulaglutide | 73.1 ± 7.6 | 68.9 ± 5.6 |
 Controls | 76.6 ± 7.1 | 76.3 ± 13.8 |
 P | 0.014 | 0.015 |
BMI (kg/m2) (mean ± SD) | ||
 Subjects treated with dulaglutide | 26.9 ± 3.4 | 25.2 ± 3.6 |
 Controls | 26.6 ± 5.0 | 27.8 ± 5.1 |
 P | 0.741 | 0.003 |
HR (bpm) (mean ± SD) | ||
 Subjects treated with dulaglutide | 75.6 ± 6.0 | 75.1 ± 5.3 |
 Controls | 78.7 ± 12.5 | 77.7 ± 12.5 |
 P | 0.097 | 0.161 |
Total cholesterol (mg/dL) (mmol/L) (mean ± SD) | ||
 Subjects treated with dulaglutide | 160.3 ± 21.2/ 4.3 ± 0.7 | 152.3 ± 22.4/3.94 ± 0.58 |
 Controls | 165.2 ± 26.3/4.2 ± 0.6 | 163.3 ± 21.5/4.22 ± 0.56 |
 P | 0.284 | 0.009 |
HDL cholesterol (mg/dL) (mmol/L) (mean ± SD) | ||
 Subjects treated with dulaglutide | 36.4 ± 4.3/0.9 ± 0.1 | 38.3 ± 5.7/ 0.99 ± 0.15 |
 Controls | 36.7 ± 4.3/0.9 ± 0.1 | 36.9 ± 4.7/0.95 ± 0.11 |
 P | 0.607 | 0.135 |
LDL cholesterol (mg/dl) (mmol/L) (mean ± SD) | ||
 Subjects treated with dulaglutide | 101.8 ± 10.6 /2.6 ± 0.2 | 96.0 ± 9.1/2.48 ± 0.24 |
 Controls | 103.8 ± 11.9/2.68 ± 0.31 | 103.2 ± 10.8/2.67 ± 0.28 |
 P | 0.339 | <0.0005 |
Triglycerides (mg/dL) (mmol/L) (mean ± SD) | ||
 Subjects treated with dulaglutide | 138.1 ± 13.2/1.5 ± 0.1 | 137.5 ± 18.9/1.55 ± 0.21 |
 Controls | 138.0 ± 15.9/1.56 ± 0.18 | 138.1 ± 18.9/2.72 ± 0.42 |
 P | 0.971 | 0.878 |
FPG (mg/dL/mmol/L) (mean ± SD) | ||
 Subjects treated with dulaglutide | 131.2 ± 21.9/7.2 ± 1.2 | 119.3 ± 14.3/6.65 ± 1.05 |
 Controls | 146.2 ± 29.5/8.13 ± 1.64 | 145.5 ± 29.6/8.09 ± 1.64 |
 P | 0.003 | <  0.0005 |
HBa1C (media ± DS) | ||
 Subjects treated with dulaglutide | 6.5 ± 0.5 | 6.2 ± 0.3 |
 Controls | 7.0 ± 0.5 | 6.9 ± 0.5 |
 P | <0.0005 | < 0.0005 |
GFR CKD-EPI (mean ± SD) | ||
 Subjects treated with dulaglutide | 76.7 ± 10.5 | 76.7 ± 9.8 |
 Controls | 76.5 ± 16.2 | 76.5 ± 16.2 |
 P | 0.954 | 0.959 |
Microalbuminuria (mg/24H) (mean ± SD) | ||
 Subjects treated with dulaglutide | 80.1 ± 16.6 | 79.1 ± 9.0 |
 Controls | 82.8 ± 18.5 | 82.5 ± 9.3 |
 P | 0.432 | 0.05 |
RHI (mean ± SD) | ||
 Subjects treated with dulaglutide | 1.8 ± 0.4 | 2.0 ± 0.4 |
 Controls | 1.8 ± 0.4 | 1.8 ± 0.4 |
 P | 0.901 | 0.023 |
PWV (m/s) (mean ± SD) | ||
 Subjects treated with dulaglutide | 10.8 ± 0.810.8 ± 0.8 | 10.6 ± 0.810.6 ± 0.8 |
 Controls | 10.9 ± 0.6 | 11.0 ± 0.6 |
 P | 0.376 | 0.015 |
AIx (%)( media ± DS) | ||
 Subjects treated with dulaglutide | 103.1 ± 6.7 | 101.8 ± 5.3 |
 Controls | 101.4 ± 3.6 | 101.9 ± 3.8 |
 P | 0.116 | 0.937 |